K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives

详细信息    查看全文

• 作者：Vivek Asati ; ^{vivekasatipharma47@gmail.com} ; Debarshi Kar Mahapatra ; Sanjay Kumar Bharti ; ^{skbharti.ggu@gmail.com}
• 关键词：Personalized medicine ; Inhibitors ; K-Ras ; Cancer ; SAR ; Signaling pathways
• 刊名：European Journal of Medicinal Chemistry
• 出版年：2017
• 出版时间：5 January 2017
• 年：2017
• 卷：125
• 期：Complete
• 页码：299-314
• 全文大小：1986 K
• 卷排序：125

文摘

Many anticancer drugs show reduced response in patients due to genetic mutations. Oncogenic K-Ras mutation is predominant in pancreatic, colon, and lung carcinomas. K-Ras is a biomarker and molecular target for personalized cancer treatment. Various peptidomimetics and bi-substrate inhibitors are under clinical trial(s).